INVA Stock Recent News
INVA LATEST HEADLINES
Innoviva (INVA) delivered earnings and revenue surprises of -78.18% and 81.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Theravance Biopharma, Inc. (NASDAQ: TBPH) has agreed to sell all of its units in Theravance Respiratory Company, LLC, representing 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK plc's (NYSE: GSK) TRELEGY ELLIPTA to Royalty.
A headline-grabbing takeover deal could be impactful for the medical community - and today, it's definitely huge news for LJPC stock holders. The post La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News appeared first on InvestorPlace.
Innoviva Inc (NASDAQ: INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average price. Innoviva will also pay an incremental $0.28 per share for additional.